Streetbeat News

Price Targets

ES

Eversource Energy's stock (ES) is trading higher following Barclays' decision to maintain an Equal-Weight rating while increasing the price target from $61 to $65.

Portfolio Pulse from Benzinga Newsdesk

January 02, 2024 | 6:05 pm

ITCI

Intra-Cellular Therapies (NASDAQ:ITCI) has received 6 analyst ratings over the past three months, with a current average 12-month price target of $84.5, up from the previous $80.00. Ratings include 2 bullish and 4 somewhat bullish, with recent actions including raises and maintains by analysts from B of A Securities, Cantor Fitzgerald, TD Cowen, RBC Capital, and Needham. The company has shown a revenue growth rate of 75.05% as of September 30, 2023, but has a net margin of -19.28% and an ROE of -4.02%, indicating potential profitability and efficiency challenges.

Portfolio Pulse from Benzinga Insights

January 02, 2024 | 6:01 pm

PH

Parker Hannifin (NYSE:PH) received varied analyst ratings in the last quarter, with 5 bullish and 1 somewhat bullish out of 6 total ratings. The average 12-month price target is $502.0, up 5.8% from the previous $474.50, with a high of $551.00 and a low of $470.00. Analysts from firms including Goldman Sachs, Wells Fargo, Stifel, Deutsche Bank, and B of A Securities have maintained or raised their ratings and price targets, reflecting positive market conditions and company performance. Parker Hannifin's financials show strong revenue growth and net margin but a higher debt-to-equity ratio than industry average.

Portfolio Pulse from Benzinga Insights

January 02, 2024 | 6:01 pm

ALKS

Analysts have provided varied ratings for Alkermes (NASDAQ:ALKS) over the last quarter, with a total of 1 bullish, 1 somewhat bullish, and 3 indifferent ratings. The average 12-month price target for ALKS is now $32.6, down from the previous $33.67. Analysts from B of A Securities, JP Morgan, Piper Sandler, Mizuho, and UBS have made recent evaluations, with some raising and others lowering their price targets. Alkermes is a biotech company with a market cap below industry average, a revenue growth rate of 50.95% as of September 30, 2023, a net margin of 12.54%, an ROE of 3.62%, an ROA of 2.14%, and a debt-to-equity ratio of 0.28.

Portfolio Pulse from Benzinga Insights

January 02, 2024 | 6:00 pm

TFC

Truist Finl (NYSE:TFC) received mixed analyst ratings over the past three months, with a recent average price target of $36.06, up from $35.00. Barclays, Odeon Capital, Piper Sandler, Morgan Stanley, Evercore ISI Group, and Raymond James provided updates, with some raising and others lowering their price targets. Truist, a regional bank resulting from the merger of BB&T and SunTrust, faces revenue challenges and below-average profitability metrics. Analysts' ratings reflect their views on the company's performance and market conditions.

Portfolio Pulse from Benzinga Insights

January 02, 2024 | 6:00 pm

CNC

Centene Corporation's stock (CNC) is trading higher following an upgrade by Wells Fargo from Equal-Weight to Overweight, with a price target increase from $82 to $90.

Portfolio Pulse from Benzinga Newsdesk

January 02, 2024 | 6:00 pm

MTTR

Matterport (NASDAQ:MTTR) received indifferent ratings from 4 analysts in the past three months, with no bullish or bearish stances. The average 12-month price target is $2.62, down from the previous $3.00. Analysts from Piper Sandler and Morgan Stanley have adjusted their price targets and ratings, reflecting a neutral outlook. Matterport's financials show a net margin of -110.12% and an ROE of -8.2%, with a debt-to-equity ratio of 0.0, indicating less reliance on debt financing.

Portfolio Pulse from Benzinga Insights

January 02, 2024 | 6:00 pm

AR

Antero Resources (NYSE:AR) received mixed analyst ratings in the past three months, with a total of 3 bullish, 1 somewhat bullish, and 2 indifferent ratings. The average 12-month price target is $30.33, down 11.32% from previous estimates, with a high of $37.00 and a low of $26.00. Analysts from firms like Raymond James and Wells Fargo have adjusted their price targets and ratings, reflecting changes in market conditions and company performance. Antero Resources is involved in natural gas and liquids exploration and production, with proven reserves and production figures reported for 2022. The company's financials show challenges in revenue growth, profitability, and returns, with a market capitalization below industry averages and a conservative debt management approach.

Portfolio Pulse from Benzinga Insights

January 02, 2024 | 6:00 pm

BIOR

HC Wainwright & Co. analyst Joseph Pantginis has reiterated a Buy rating on Biora Therapeutics (NASDAQ:BIOR) and maintained a $50 price target on the company's stock.

Portfolio Pulse from Benzinga Newsdesk

January 02, 2024 | 5:11 pm

SNDX

HC Wainwright & Co. analyst Edward White has reiterated a Buy rating on Syndax Pharmaceuticals (NASDAQ:SNDX) and maintained a price target of $41.

Portfolio Pulse from Benzinga Newsdesk

January 02, 2024 | 5:07 pm